LIFESPLICE PHARMA, LLC
Biotech · Private
Splice modulating oligonucleotides (SMOs) that redirect SCN8A pre-mRNA splicing to reduce functional sodium channel protein for Dravet Syndrome treatment
- Grants
- $2.6M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 1 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Preclinical testing of the splice modulating oligonucleotide LSP-GR1 | $1,033,937 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical testing of the splice modulating oligonucleotide LSP-GR1 | $965,278 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Testing of Splice Modulating Oligonucleotides Targeting SCN8A to Treat Dravet Syndrome | $389,793 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Testing of Splice Modulating Oligonucleotides Targeting SCN8A to Treat Dravet Syndrome | $185,688 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2454 | TERAPORE TECHNOLOGIES, INC. | — | $3.5M |
| 2455 | Plexium | — | $60M |
| 2456 | Prolific Machines | — | $55M |
| 2457 | LIFESPLICE PHARMA, LLC | — | — |
| 2458 | ImmusanT, Inc. | — | $33M |
| 2459 | GALECTIN THERAPEUTICS INC | — | $6.8M |
| 2460 | Eidos Therapeutics | — | $26M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Splice Modulating Oligonucleotides Targeting Receptor For Advanced Glycation End Products And Methods Of Useapplication
- Splice Modulating Oligonucleotides And Methods Of Use Thereofapplication
- SCN8A Splice Modulating Oligonucleotides And Methods Of Use Thereofgranted
- Splice Modulating Oligonucleotides Targeting Receptor For Advanced Glycation End Products And Methods Of Useapplication
- Splice Modulating Oligonucleotides Targeting Receptor For Advanced Glycation End Products And Methods Of Useapplication
- Splice Modulating Oligonucleotides Targeting Receptor For Advanced Glycation End Products And Methods Of Useapplication
- Splice Modulating Oligonucleotides Targeting Receptor For Advanced Glycation End Products And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.